mg launch drive beat rais
top bottom line beat guidanc up
report revenu consensu driven
strong soliri perform ep beat consensu driven lower
cost updat revenu guidanc includ
soliri includ fx headwind unfavor impact
soliri enrol alreadi realiz thu far
non-gaap guidanc updat revenu oper
margin guidanc increas adjust ep guidanc rais
adjust adjust ep reiter
buy consist growth base busi strong gmg launch
gmg launch take top-line growth next level
us gmg patient soliri therapi end septemb
enrol onesourc system reiter expect gmg
best soliri launch thu far expect see current trajectori continu
note rais full year revenu guidanc larg driven gmg out-performance
strong underli growth soliri pnh ahu gmg continu
bolster alxn top-line growth potenti nmosd offer top-line
expans come year nmosd file expect
addit financi result also announc collabor dicerna
discov develop rnai therapi complement-medi diseas
help diversifi alxn pipelin beyond target diseas
ultomiri fda approv expect februari phase
bridg studi subcutan weekli ultomiri expect initi year end
initi studi ultomiri gmg expect stock
experienc weak despit strong quarter like due concern around chugai
phase data pnh expect annual meet american societi
hematolog addit regn phase data note competitor
lag behind ultomiri least two year pose near-term threat
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani market
soliri monoclon antibodi therapi
treatment ultra-rar diseas includ
paroxysm nocturn hemoglobinuria pnh
compani also market strensiq treatment
hypophosphatasia kanuma lal-d
focu sever life threaten ultra rare
rate buy expect industri
growth compani market product soliri
success launch new product
strensiq kanuma see upsid risk street
estim addit pipelin
momentum creat news flow
price object base discount cash flow analysi use
wacc termin growth rate
downsid risk failur meet expect soliri sale and/or launch
strensiq asfotas alfa kanuma lal-d govern drug price
focu ultra-orphan product failur advanc key pipelin product includ
soliri new indic
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
